Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 8
States / cities: Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: VeraLight, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hyattsville, Maryland

Conditions: Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
Interventions: TKM-080301; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more

Conditions: Diabetes
Interventions: Patient Activation and Diabetes Registry; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, placebo, sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin Degludec, Insulin Glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Los Angeles, California + 15 more

Conditions: Type 1 Diabetes, Pregnancy
Interventions: Frequent remote contact between clinic visits.; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Retinopathy
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: insulin regular IV infusion, IV insulin infusion; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Standard of care; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 180
States / cities: Buena Park, California • Burbank, California • Costa Mesa, California + 144 more

Conditions: Diabetes
Interventions: CO-IMPACT, PACT; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 70 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Clamp; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 9 Years to 23 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: PreDiabetes
Interventions: GEM, Routine Care; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: SI-Informed Bolus Calculator; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypertension, Diabetes, Dyslipidemia
Interventions: Medication Adherence Smartphone App; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Little Rock, Arkansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Dietary treatment; Behavioral
Lead sponsor: Manassas Internal Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: GLP - 1, Diabetes, Obesity and Obesity-related Medical Conditions, Cardiovascular Diseases
Interventions: Health Coach/Fitbit; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Sashwati Roy; Other
Eligibility: 40 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreatic Cancer
Interventions: Alcohol Block; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Polycystic Ovary Syndrome, Hormone Imbalance
Interventions: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement; Dietary Supplement
Lead sponsor: Optify; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Diabetic Retinopathy, Diabetes Mellitus
Interventions: Aim 3: Contract; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreas Cancer
Interventions: TG01 Vaccine, QS-21, Balstilimab; Biological · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Arginine and fish oil; Dietary Supplement
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2, Depression, Anxiety, Diet Habit
Interventions: Not listed
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Santa Barbara, California

Search by objective public record fields.

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

The ABC Planning Study: Diabetes and Cardiovascular Risks in Primary Care

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes

Sirolimus to Treat Diabetic Macular Edema

Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Caring Others Increasing EngageMent in PACT

Insulin Resistance in Type I Diabetes in Pediatric Care

CGM Plus GEM in Prediabetes

Safety and Feasibility of an Insulin Sensitivity-Informed Bolus Calculator in Type 1 Diabetes

Is a Smartphone Application Effective as an Oral Medication Adherence Aid

Trial of New Dietary Treatment of Diabetes

FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support

Leukocyte Dysfunction in Diabetic Patients.

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Treatment of Type 2 Diabetes With Immunonutrients

Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes: